Evidence mapPaperPMID 41310280Full record

ReviewDiscover oncology2025

AMPK: an enzyme that may be effective in cancer and metabolic diseases.

Sümeyye Güney Kalkan, Meltem Ceylan Ünlüsoy

Abstract readReview
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sümeyye Güney KalkanAnkara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara, Türkiye.
Meltem Ceylan ÜnlüsoyAnkara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara, Türkiye. munlusoy@pharmacy.ankara.edu.tr.

Funding

The Scientific and Technological Research Council of Türkiye 220S193
6 · The paper itself

Abstract

Diseases are processes that feed on the interaction and triggering of impairments in cellular metabolism. The fact that AMPK has arresting and initiating effects on anabolic-catabolic processes shows that it plays a key role in the functioning of metabolism and especially energy metabolism. The effects of AMPK on fat, carbohydrate, and protein metabolism, as wel as on growth, and autophagy have made AMPK an important target in chronic diseases such as Type 2 diabetes, metabolic syndrome, obesity, inflammation, cancer treatment, and even anti-aging. Considering the other effects of AMPK, the possibility that it can exhibit an anticancer effect through a mechanism other than just suppressing the cell growth and division cycle and activating autophagic pathways is within the realm of possibility. It has been stated that suppression of AMPK will trigger glycolysis in some cancer cells and increase the Warburg effect, which is effective in the energy production of cells. Besides, it has been reported recently that inflammation is a major factor in the development of tumors and that chronic inflammation raises the risk of cancer. This enzyme, that is known to be effective in all metabolic pathways, has attracted attention in the treatment of metabolic diseases. Therefore, this study aims to provide some information about the AMPK enzyme, the role of AMPK in cancer, metabolic disorders, and developed AMPK activators.

Indexed as

AMPKAMPK activatorsCancerInflammationMetabolic syndrome

Identifiers

PMID41310280
PMCPMC12748415

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.